Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DAWN vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DAWN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

DAWN Overall Winner 6-Pillar Tally: DAWN 3 – 2 DSGN (1 Tie) Matrix Metrics: DAWN 6 – 2 DSGN

As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). DAWN carries a Unified Composite Score of 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DAWN vs DSGN
DAWN NASDAQ Head-to-Head Winner
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
TTM Revenue $158M
Forward P/E N/M
Beta / 30D Vol 0.03β · 2% Vol
Unified Composite Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (28.9% over 20 days), RSI 80
RSI-14: 80.5 · SMA20: $21.45 · SMA50: $18.01
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $10.53 · SMA50: $11.58

6-Pillar Scorecard Institutional Category Breakdown (DAWN 3 – 2 DSGN)

Columns: Metric · DAWN · DSGN
1. Valuation Multiples DAWN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 14.0x N/M
2. Growth & Scale DAWN
Revenue Growth (YoY) +83.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $158M $33,000
Market Cap $2.2B $677.5M
3. Profitability & Quality DSGN
Gross Margin 89.1% N/A
Operating Margin -51.1% 0.0%
Net Profit Margin -67.8% 0.0%
Return on Equity (ROE) -22.7% -36.9%
4. Balance Sheet & Cash Flow DSGN
Cash Generation (TTM) -$124M EBITDA -$59M
Cash Flow Margin -78.6% EBITDA Mgn N/A
Net Cash / Leverage $4.28 Book/Sh · -22.7% ROE $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DAWN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 0.6% (<1st %ile) 92.0% (13th %ile)
Put/Call OI Skew 0.45x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DAWN (6) vs DSGN (2)
Institutional Metric DAWN DSGN Criterion Row Edge
Market Capitalization
Scale
$2.2B $677.5M Larger Scale DAWN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+83.9% +0.0% Higher Growth DAWN
Operating Margin (TTM)
Profitability
-51.1% 0.0% Higher Margin DSGN
Net Profit Margin
Profitability
-67.8% 0.0% Higher Margin DSGN
Return on Equity (ROE)
Capital Efficiency
-22.7% -36.9% Higher ROE DAWN
52-Week Range Position
Momentum
100% ($6–$22) 30% ($7–$17) Stronger Trend DAWN
Beta / 30D Volatility
Risk Regime
0.03β · 2% Vol 1.32β · 61% Vol Lower Realized Risk DAWN
Unified Institutional Score
Composite Signal
58.3 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite DAWN
Trailing 12M Revenue (USD)
Operating Scale
$158M $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$124M EBITDA ($4.28 Book/Sh · -22.7% ROE) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DSGN +30.67 pp
DAWN: +0.8% · DSGN: +31.47%
3M Horizon DAWN +38.38 pp
DAWN: +78.38% · DSGN: +40.0%
6M Horizon DAWN +53.9 pp
DAWN: +143.28% · DSGN: +89.38%
1Y Horizon DAWN +53.9 pp
DAWN: +143.28% · DSGN: +89.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DAWN vs DSGN. Trailing 12-month operating profitability (DAWN -51.1% vs DSGN 0.0%) and valuation multiples (DAWN N/M vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DAWN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$158M
Gross Margin89.1%
Op. Margin-51.1%
ROE / Fwd P/E-22.7% · N/M
DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DAWN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact DAWN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DAWN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DAWN vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). DAWN carries a Unified Composite Score of 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DAWN leads the Growth & Scale pillar: DAWN posts +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DAWN generates $158M in USD-normalized revenue versus $33,000 for DSGN. In operating R&D and SG&A reinvestment, DAWN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

DAWN screens cheaper on headline valuation multiples. DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DAWN (-22.7% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.